In 2017, based on the demonstration that each of the tumor’s components harbors a distinct somatic mutation (i.e., BRAF mutation in the epithelial component and CTNNB1 mutation in the mesenchymal component), we proposed the term “papillary thyroid carcinoma with desmoid-type fibromatosis” (PTC-DTF) [4]. This evidence concerns the gene BRAF and neoplasm.